Market Overview

UPDATE: BMO Capital Markets Initiates Intercept Pharmaceuticals at Outperform on Outlook

Share:
Related ICPT
Intercept Pharma Shares Higher Following New Buy Rating, $465 Target From UBS
Biotech Investors: Nomura Says To Watch These Dates
Intercept Pharmaceuticals Releases Data on Lead Drug - Analyst Blog (Zacks)

BMO Capital Markets initiated coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with an Outperform rating and a $31 price target.

BMO Capital Markets said, "Our positive outlook is supported by a proprietary platform of bile acid analogs, a deep pipeline of clinical candidates, and a lead opportunity in Primary Biliary Cirrhosis (PBC), a rare orphan disease supporting a $500 million–$1 billion opportunity. With phase 3 data for lead bile acid analog OCA (INT-747) expected by mid-2013, phase 2 data in PBC is compelling, in our opinion, and should support a clear benefit in patients failing current standard bile acid therapy with ursodiol (URSO)."

Intercept Pharmaceuticals closed at $18.75 on Friday.

Latest Ratings for ICPT

DateFirmActionFromTo
Apr 2015UBSInitiates Coverage onBuy
Mar 2015Janney CapitalMaintainsBuyBuy
Mar 2015Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ICPT)

Around the Web, We're Loving...